[PDF] Top 20 HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

... served clear-cell ...for HIF-1 α (Cell Signaling), 1:500 dilution for HIF-2 α (Nous Biologicals) and 1:300 dilution for c-Myc (DD ... See full document

... of sunitinib at Akita University Hospital and at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, were enrolled in this institutional, review-board-approved, retrospect- ive ...of ... See full document

... treating clear-cell ...T cell infiltrates at baseline, day 8 of cycle 2 (biopsy), and day 2 of cycle 1 (serum) ...overall response rate, safety/tolerability, and treatment-induced changes in ... See full document

... The 56-year old Chinese patient underwent radical resection and was diagnosed with renal clear cell carcinoma (stage II) in 2015. Diagnosis of the disease was based on magnetic resonance (MR) ... See full document

... had metastatic ccRCC confirmed by histology, with the presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) ...for sunitinib or bevacizumab combined with ... See full document

... which clear cell RCC (ccRCC) is the most frequent (75– 80%), followed by papillary RCC (pRCC; 15%) and chro- mophobe RCC (chRCC; 5%) [6], and biallelic von-Hippel Lindau (VHL) gene defects occur in ... See full document

... in renal cancer progression ...regulate HIF activation. Once activated, HIF transcription factors translocate in the nucleus and bind to the hypoxia response elements which leads to ... See full document

... to sunitinib rather than progression of the disease; agreeing with previous work refuting a link between VHL inactivation and aggressive ccRCC ...to sunitinib showed a high degree of VHL methylation ... See full document

... to sunitinib rather than progression of the disease; agreeing with previous work refuting a link between VHL inactivation and aggressive ccRCC ...to sunitinib showed a high degree of VHL methylation ... See full document

... for metastatic RCC (mRCC), and primary therapy resist- ance, reduced quality of life and short survival were major challenges in this patient ...the clear cell carcinomas: cy- tokines and immune ... See full document

... with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical ...of metastatic sites (HR = ... See full document

... similarly high sensitivity and specificity (70.4% and 69.4%, respectively). The second cut-off (68.67 HU) showed a very high specificity and a good sensitivity (80.6% and 59.3%, respectively), which underline its ... See full document

... objective response rate and progression-free survival have been introduced as surrogate endpoints that have utility and convenience for comparison of trial arms but have arguable relationship to patient-centered ... See full document

... induces HIF expression and ...Whole cell lysates were prepared and analysed by western blot for the indicated non-canonical NF- κ B pathway regulators, subunits and target ...0.001. C) HeLa ... See full document

... study, bone metastases have not been related to OS. Median first-line systemic therapy progression-free sur- vival (PFS) was 8 months for the “targeted therapy” cohort patients. This finding could appear lower than the ... See full document

... A number of potential causes should be ruled out. Fatigue may be caused or exacerbated by underlying dehydration. Adequate fluid and nutri- tional intake should be ensured. Laboratory and clinical evaluations should be ... See full document

... with sunitinib (n=577) and pazopanib ...International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups ...with sunitinib had improved OS compared with ... See full document

... tissue in a case of metastatic clear cell renal cell carcinoma, a case of papillary thyroid cancer and two 356. cases of prostate cancer[r] ... See full document

... It is widely accepted that renal cancer is largely resistent to chemotherapy in the majority of patients. The data presented here describes 11 patients who switched to IPM chemotherapy at progression (n = 10) or ... See full document

... In conclusion, RCC patients with somatically mutated PBRM1 tend to have higher TMB than those without it. The somatically mutated DDX51 is an independent risk factor for DFS among RCC patients and could be a new ... See full document